↓ Skip to main content

Cochrane Database of Systematic Reviews

Haloperidol versus placebo for schizophrenia

Overview of attention for article published in Cochrane database of systematic reviews, November 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
6 tweeters
facebook
1 Facebook page
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
278 Mendeley
Title
Haloperidol versus placebo for schizophrenia
Published in
Cochrane database of systematic reviews, November 2013
DOI 10.1002/14651858.cd003082.pub3
Pubmed ID
Authors

Clive E Adams, Hanna Bergman, Claire B Irving, Stephen Lawrie

Abstract

Haloperidol was developed in the late 1950s for use in the field of anaesthesia. Research subsequently demonstrated effects on hallucinations, delusions, aggressiveness, impulsiveness and states of excitement and led to the introduction of haloperidol as an antipsychotic.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 278 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 <1%
United Kingdom 1 <1%
India 1 <1%
Portugal 1 <1%
Unknown 273 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 48 17%
Student > Bachelor 33 12%
Researcher 32 12%
Student > Ph. D. Student 30 11%
Other 15 5%
Other 58 21%
Unknown 62 22%
Readers by discipline Count As %
Medicine and Dentistry 87 31%
Psychology 41 15%
Nursing and Health Professions 21 8%
Pharmacology, Toxicology and Pharmaceutical Science 12 4%
Neuroscience 8 3%
Other 39 14%
Unknown 70 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2020.
All research outputs
#1,497,272
of 23,861,318 outputs
Outputs from Cochrane database of systematic reviews
#3,402
of 12,767 outputs
Outputs of similar age
#14,126
of 214,256 outputs
Outputs of similar age from Cochrane database of systematic reviews
#77
of 239 outputs
Altmetric has tracked 23,861,318 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,767 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.6. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 214,256 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 239 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.